Flexion Therapeutics (FLXN) said on Friday the U.S. Food and Drug Administration has approved Zilretta, intra-articular injection for osteoarthritis (OA) knee pain.

The drugmaker said the drug is a non-opioid medicine using its proprietary microsphere technology to provide proven pain relief over 12 weeks.

“OA knee pain presents a host of challenges for patients and clinicians alike, and there has been very little innovation in this area in recent years,” said Andrew Spitzer, co-director of Cedars-Sinai Orthopaedic Center. “Zilretta is a groundbreaking new therapy, providing clinically meaningful pain relief with a safety profile that is similar to saline.”

Flexion shares were 10% higher in late trade, earlier hitting a 52-week high.

Fatal error: Call to undefined function printFooterForm() in /home3/boost/public_html/westoverreview.com/wp-content/themes/alpha/single.php on line 57